In particular, an activating point mutation in JAK2 (JAK2V617F) was described as being highly frequent in chronic myeloproliferative neoplasms (MPN) that promote disease progression [81,82,83,84]. This evidence concerns the gene JAK2 and myeloproliferative disorder.